Bayer BAYRY has announced an exclusive license agreement with Cedilla Therapeutics to jointly develop and commercialize the latter’s CyclinE1/CDK2 complex inhibitors for targeted oncogenic ...

Cedilla Therapeutics, an oncology biotech founded by a former Editas executive, has snagged an additional $25 million to bring two small-molecule oncology programs into human trials. The financing ...

Cedilla Therapeutics, a biotechnology company bringing a new dimension to precision oncology, today announced that it has raised an additional $25 mil Cedilla Therapeutics Completes $82.6M Series ...

Cedilla Therapeutics launched Tuesday with a $56 million investment from Third Rock and a mission to develop small molecules that target the stability of cancer-driving proteins. Others have ...

Bayer BAYRY has announced an exclusive license agreement with Cedilla Therapeutics to jointly ... growth stock and 4 other "must buys." Plus more.

Cedilla Therapeutics, a biotechnology company bringing a new dimension to precision oncology, today announced that it has raised an additional $25 million in ...